The T3→T2 Conversion Problem: Why T3 Protocols Plateau

The T4-to-T3 conversion problem is well-understood in the chronic-illness research community. T4 (levothyroxine) is a prohormone. To become biologically active, it requires enzymatic deiodination - the removal of a single iodine atom - to produce T3. Wilson's Protocol was built on the recognition that this conversion step is not always intact: inflammation, selenium deficiency, elevated cortisol, and low ferritin can impair the deiodinase enzymes responsible, leaving research subjects with adequate T4 supply but functionally hypothyroid T3 output. The WT3 protocol bypasses this bottleneck by delivering T3 directly.

What the Wilson's framework addresses only partially is what happens next. Once T3 is present - whether produced endogenously from T4 or delivered exogenously - the body must convert a portion of it into the downstream metabolite 3,5-T2 (3,5-diiodothyronine). That second conversion step uses the same deiodinase enzyme family that controls the first. If DIO1 is impaired by selenium deficiency, inflammation, or chronic illness - the exact conditions that drove the need for T3 protocol in the first place - T3-to-T2 conversion is impaired by the same mechanism at the same time.

The thesis of this article is specific: the T3 protocol plateau that researchers and research subjects frequently encounter is not always explained by the reverse-T3 mechanism alone. A significant fraction of plateau patterns may represent incomplete T3→T2 conversion, leaving mitochondrial function - which depends specifically on T2's cytochrome c oxidase pathway - inadequately supported despite T3 levels that appear sufficient on standard serum panels.

Research framing. This article reviews the T3-to-T2 conversion pathway from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.

The First Conversion: T4 → T3 (The Well-Known Problem)

Wilson's Temperature Syndrome - the clinical framework that underlies the WT3 protocol - is built on a documented biochemical reality. T4 is a prohormone. It becomes metabolically active when the type 1 deiodinase (DIO1) or type 2 deiodinase (DIO2) removes an iodine atom from the outer ring, producing T3. Under ideal conditions, this conversion runs efficiently and the body maintains adequate free T3 throughout the day.

Under the conditions that characterize chronic illness, the conversion is impaired. The factors that block T4→T3 conversion are well-catalogued in the research literature:

• Selenium deficiency. All three deiodinases (DIO1, DIO2, DIO3) are selenoproteins - they require selenium as a cofactor to function. Selenium deficiency degrades their activity across the board.
• Systemic inflammation. Cytokines - particularly IL-6, TNF-alpha, and IL-1beta - suppress DIO1 activity and upregulate DIO3 activity, shifting the deiodinase balance away from T3 production.
• Elevated cortisol. Chronic stress and cortisol elevation push the deiodinase system toward producing reverse T3 (rT3) rather than active T3, via increased DIO3 activity.
• Low ferritin. Iron is required for hepatic T4-to-T3 conversion; ferritin below approximately 70 ng/mL is associated with impaired conversion in multiple case series.
• DIO2 polymorphisms. The Thr92Ala single-nucleotide polymorphism in DIO2 reduces enzyme efficiency, creating a genetically-driven conversion impairment in affected individuals.

The result of these combined inputs is the classic reverse-T3 dominance pattern: rT3 accumulates (produced by DIO3 acting on T4), free T3 falls, and TSH may appear normal or even slightly elevated despite functional hypothyroidism at the tissue level. For a complete analysis of the reverse-T3 mechanism and FT3:rT3 ratio interpretation, see the reverse T3 complete guide.

Wilson's Protocol addresses this by delivering T3 directly and in sustained-release form - using sustained-release T3 (SR-T3) to bypass the impaired T4→T3 conversion step entirely. The WT3 cyclic titration is designed to overwhelm the deiodinase imbalance producing the rT3 pattern and then taper out, allowing endogenous conversion to resume at a corrected baseline. It is a well-reasoned protocol for the T4→T3 bottleneck. The question this article addresses is why so many research subjects plateau before reaching that corrected baseline.

The Second Conversion: T3 → T2 (The Less-Discussed Problem)

T3 is not the terminal product of thyroid hormone metabolism. Once T3 is present - whether from endogenous T4 conversion or from exogenous T3 administration - the deiodinase system continues processing it. The primary downstream pathway involves DIO1 acting on T3 to remove the 3'-iodine from the outer ring, producing 3,3'-T2 (3,3'-diiodothyronine). This is the best-characterized T3→T2 conversion pathway and represents the main enzymatic route for T3 catabolism in peripheral tissues.

The second and metabolically more significant downstream product is 3,5-T2 (3,5-diiodothyronine). The production pathway for 3,5-T2 from T3 is less precisely characterized in the peer-reviewed literature than the DIO1→3,3'-T2 pathway - its in-vivo synthesis is still being elucidated. What is documented is that 3,5-T2 is present in human serum at measurable concentrations, that its presence correlates broadly with T3 availability, and that the deiodinase machinery involved in thyroid hormone catabolism broadly is the enzyme family through which this conversion proceeds. DIO1 is implicated in multiple deiodination steps across the thyroid hormone family; the same enzymatic context that produces 3,3'-T2 from T3 overlaps with the machinery producing the active 3,5-T2 isomer.

The practical significance is straightforward. If a research subject is receiving exogenous T3 via a WT3 or combination protocol, the question is not only whether T3 is reaching its nuclear receptors - it is whether downstream conversion to 3,5-T2 is occurring at a rate sufficient to support mitochondrial function. T3 and T2 address different physiological targets through different mechanisms. Supplementing T3 and assuming the downstream T2 supply will follow assumes that T3→T2 conversion is intact. In the population already characterized by deiodinase dysfunction, that assumption requires examination.

Why the Same Dysfunction Blocks Both Steps

The enzymatic overlap between the T4→T3 step and the T3→T2 step is not coincidental - it reflects the structure of the deiodinase enzyme family itself. The three human deiodinases (DIO1, DIO2, DIO3) are all selenoproteins with a shared catalytic core, all requiring selenium in the form of selenocysteine at their active site. The same selenium insufficiency that impairs T4→T3 conversion impairs T3→T2 conversion through the same mechanism: inadequate selenoprotein synthesis reduces the functional activity of the entire deiodinase family simultaneously.

The inflammation pathway follows the same logic. When IL-6, TNF-alpha, and related inflammatory cytokines suppress deiodinase activity in peripheral tissues, that suppression is not limited to the T4→T3 step. The same inflammatory signaling environment that reduces DIO1's conversion of T4 to T3 also reduces DIO1's ability to process T3 into its downstream products. A research subject in a high-inflammation state is not just failing to convert T4 to T3 adequately - they are failing to process T3 through the full metabolic cascade that would normally produce T2 as a downstream product.

The reverse-T3 mechanism adds another layer. Elevated DIO3 activity - the primary driver of rT3 accumulation - competes with DIO1 for T4 substrate. Under DIO3 dominance, T4 is preferentially diverted toward rT3 rather than active T3. The consequence is reduced T3 availability, which means reduced substrate for T3→T2 conversion as a downstream effect. Even when exogenous T3 is introduced to bypass the T4→T3 bottleneck, the elevated DIO3 activity and overall deiodinase imbalance may continue to impair the processing of that exogenous T3 into T2.

The summary: the conditions that create the original need for a T3 protocol - selenium deficiency, inflammation, cortisol excess, DIO imbalance - are precisely the conditions that will impair T3→T2 conversion in the same research subject. Addressing the T4→T3 step without addressing the T3→T2 step is an incomplete solution for subjects in whom both steps are blocked.

The Clinical Signal: The T3 Protocol Plateau

The T3 protocol plateau is a recognizable pattern in the research-community literature and forum discussions surrounding thyroid optimization. A research subject begins a T3 protocol - typically the Wilson's WT3 cyclic approach or a combination T4+T3 regimen - and experiences an initial improvement in the markers they are tracking: body temperature rises toward 98.6°F, energy improves, cognitive clarity increases. Then, at some point in the titration, the improvements stop. Not dramatically - the subject does not regress to baseline - but additional T3 dose increases produce diminishing returns or no further benefit.

The standard interpretation of this pattern is residual rT3 dominance: the deiodinase imbalance is not fully corrected, DIO3 activity continues to generate rT3 faster than the T3 dose can overwhelm it, and the plateau represents an equilibrium between exogenous T3 supply and ongoing rT3 production. This explanation accounts for a subset of plateau patterns, and the standard WT3 response - continue titrating, sustain temperature for three consecutive weeks, then taper - is the correct protocol for the rT3-dominant plateau.

But researchers tracking the plateau pattern more granularly have noted cases where the rT3 explanation does not fit cleanly. Free T3 measured in serum is not low - it may be in the upper third of the reference range or even slightly above it. TSH is appropriately suppressed. rT3 has been measured and is not dramatically elevated. By the standard thyroid-panel metrics, the T3 protocol appears to be working. Yet the subject reports temperature stabilizing at 97.8°F rather than 98.6°F, persistent fatigue that the T3 dose does not resolve, and body composition that refuses to shift despite an otherwise functional-looking thyroid panel.

This presentation - adequate free T3, suppressed TSH, normalized rT3, yet persistent metabolic underperformance - is the signal that researchers have begun to associate with the T3→T2 conversion bottleneck. The genomic thyroid signaling pathway served by T3 appears intact. What is not adequately restored is the mitochondrial pathway that depends specifically on T2 - the pathway through which cellular energy production is directly modulated at the Complex IV level, independent of anything a nuclear receptor can accomplish.

Why It Matters: T2 Is the Mitochondrial Hormone

The distinction between T3 and 3,5-T2 is not a matter of degree - it is a matter of mechanism. T3 acts primarily through a genomic pathway: it binds nuclear TRalpha and TRbeta receptors, drives gene transcription, and produces metabolic effects over a 6-48 hour window as the resulting proteins accumulate. This genomic cascade is responsible for the broad thyroid hormone signature - the regulation of basal metabolic rate genes, mitochondrial biogenesis factors, and the metabolic enzyme profile of peripheral tissues.

3,5-T2 acts through a fundamentally different channel. As established by Goglia and colleagues in the landmark 1994 paper in FEBS Letters, 3,5-T2 binds directly to subunit Va of cytochrome c oxidase - the terminal enzyme of the mitochondrial electron transport chain, Complex IV - and acutely elevates aerobic respiration without requiring nuclear receptor activation or protein synthesis. The effect is measurable within minutes. T3 cannot replicate this specific pathway regardless of how much of it is present. This distinction matters enormously for the plateau discussion: a research subject with adequate serum T3 may still have suboptimal mitochondrial respiration at the Complex IV level if T2 production from T3 is insufficient.

The cytochrome c oxidase pathway is the primary mechanism through which T2 drives rapid metabolic rate elevation, fatty acid oxidation acceleration, and the thermogenic effects that distinguish T2 from T3 in side-by-side rodent-model comparisons. It is also the pathway that is specifically impaired in several chronic illness states - including post-viral conditions and chronic fatigue presentations - where Complex IV activity has been measured and found reduced. For a complete review of the T2 mechanism, the isomer-specificity question, and the TSH-safety profile that makes T2 research viable alongside T3 protocols, see the 3,5-T2 complete guide.

The practical implication for the plateau discussion is direct. If T3→T2 conversion is intact, an adequate T3 dose will produce both adequate nuclear receptor signaling and adequate T2 for the cytochrome c oxidase pathway. If T3→T2 conversion is impaired - by the same selenium deficiency and inflammation that drove the original need for T3 supplementation - the nuclear receptor pathway may be adequately served while the mitochondrial pathway remains undersupported. Measuring free T3 confirms the first; it tells you nothing about the second.

The Solution: Supplement Both T3 and T2 Directly

If both the T4→T3 and T3→T2 conversion steps are blocked by the same underlying deiodinase dysfunction, the logical extension of the Wilson's Protocol framework is to bypass both steps by supplying T3 and T2 as separate, direct inputs. T3 addresses the genomic thyroid signaling pathway directly, without requiring conversion from T4. T2 addresses the mitochondrial cytochrome c oxidase pathway directly, without requiring conversion from T3.

The 1:1 mcg ratio of T3 to T2 is the formulation rationale of the Wilson's T3+T2 Combo. The thinking is straightforward: in a research subject with intact T3→T2 conversion, the body would produce T2 as a downstream product of T3 at rates determined by DIO1 activity. A 1:1 supplementation ratio does not attempt to replicate exact physiological proportions - those are highly individual and variable - but it ensures that both the T3 supply and the T2 supply are present at relevant research-context doses simultaneously, regardless of whether endogenous conversion from T3 to T2 is functional.

The advantages of this combined approach over simply increasing T3 dose to achieve more downstream T2 production are significant. First, adding more T3 to address T2 deficiency worsens HPT-axis suppression, increasing the risk of the cardiovascular and bone-density concerns that accompany sustained TSH suppression. Second, if conversion is genuinely impaired, adding more T3 substrate does not solve the conversion problem - it increases T3 accumulation without proportionally increasing T2 output. Third, T2's nuclear receptor affinity is approximately 10-60x lower than T3's, meaning T2 supplementation adds mitochondrial activation without the same HPT-axis cost that equivalent metabolic output from additional T3 would carry.

For the full protocol structure implementing this combination - titration approach, timing, how the T2 component integrates with the WT3 cyclic framework - see the Wilson's T3+T2 enhanced protocol. The Wilson's T3+T2 Combo is the reference product for this research application, formulated at the 1:1 ratio in sustained-release capsules.

What This Looks Like in Practice

In the research-community literature on T3+T2 combination protocols, the practical implementation closely mirrors the established Wilson's WT3 approach - but with a T2 component added at a 1:1 ratio to the T3 dose at each titration step. The T3 component continues to serve as the primary driver of HPT-axis signaling and nuclear receptor activation; the T2 component runs in parallel as the mitochondrial activator.

The sustained-release formulation principle applies to both components. The same pharmacokinetic arguments that favor sustained-release T3 over immediate-release Cytomel - flatter serum curve, reduced cardiovascular peak effects, better receptor saturation continuity - apply to the combined T3+T2 preparation. A formulation that releases both T3 and T2 over the same 4-8 hour window ensures that the mitochondrial activation by T2 and the genomic signaling by T3 occur in the same temporal window rather than as separate, uncoordinated pulses.

Dose ranges discussed in research forums are as follows. The titration steps and timing structure map onto the detailed protocol in the Wilson's T3+T2 enhanced protocol guide, which should be the primary reference for any researcher designing a T3+T2 investigation.

The cyclic structure of the WT3 protocol - titrate up to temperature target, sustain for three consecutive weeks, taper down, allow endogenous function to reset - applies to the T3+T2 combination approach in the same way. The taper removes both T3 and T2 simultaneously, allowing the deiodinase system to resume endogenous production of both molecules if the underlying nutritional and inflammatory drivers of dysfunction have been addressed in the interim.

What Research Has and Hasn't Established

A consistent feature of the best research-community writing on thyroid optimization is honesty about the evidence tier for each claim. The T3→T2 conversion problem framework sits at a specific location in the evidence hierarchy, and it is worth stating that location clearly.

Established:

The foundational mechanisms supporting this framework are well-documented in the peer-reviewed literature. DIO1 produces 3,3'-T2 from T3 as its primary catabolic route - this is established deiodinase biochemistry. Selenium is a required cofactor for all three deiodinases (DIO1, DIO2, DIO3); selenium deficiency impairs deiodinase activity across the family - this is well-replicated in both animal models and clinical observations. Inflammation, specifically via cytokine-mediated suppression, degrades DIO activity broadly - also well-documented. 3,5-T2 binds cytochrome c oxidase subunit Va and directly elevates mitochondrial respiration - established by the 1994 Goglia et al. paper and supported by subsequent replication. T2 produces mitochondrial effects that T3 does not fully duplicate, particularly in the acute non-genomic timeframe - established in rodent-model literature with reasonable consistency.

Hypothesis:

The T3→T2 conversion bottleneck as a distinct clinical entity - one that explains the specific plateau pattern of adequate free T3 with persistent metabolic underperformance - is a research-community hypothesis. The mechanistic logic is solid: the same conditions that create the T4→T3 bottleneck will impair the T3→T2 step via the same selenoprotein cofactor requirement and the same inflammatory suppression pathway. But the specific clinical identification of this pattern - as distinct from rT3 dominance, from receptor resistance, from cortisol interference - has not been validated in controlled clinical trials. The T3+T2 combination approach as a solution to this plateau has not been tested in randomized controlled studies. What exists is mechanism-based reasoning built on solid individual components, applied to a clinical pattern that is consistently reported but not formally characterized.

Not endorsed by mainstream endocrinology:

The entire framing of this article - T3 protocols as a framework for addressing deiodinase dysfunction, the T3 plateau as a clinical entity, T2 supplementation as a solution to a downstream conversion problem - is research-community theory that lies outside the current standard-of-care endocrinology framework. Mainstream endocrinology does not recognize Wilson's Temperature Syndrome as a formal diagnosis, does not endorse T3-only or T3-dominant protocols for most hypothyroid presentations, and does not include T2 supplementation in any clinical guideline. Researchers engaging with this framework should be aware they are working with a mechanistically-grounded but clinically unvalidated model, and should apply appropriate experimental rigor, monitoring, and caution.

Frequently Asked Questions

What is the T3→T2 conversion problem?

The T3→T2 conversion problem refers to the hypothesis that the same deiodinase enzyme dysfunction that impairs T4→T3 conversion in chronic-illness states also impairs the downstream conversion of T3 to 3,5-T2 - the mitochondrially active thyroid metabolite. If both conversion steps are blocked, supplementing T3 alone addresses the nuclear receptor signaling pathway but leaves the mitochondrial cytochrome c oxidase pathway undersupported. The practical consequence is a T3 protocol plateau: metabolic markers stall despite adequate serum T3, because T3 availability does not automatically translate to T2 availability when the conversion enzymes are impaired.

How is it different from the T4→T3 conversion problem?

The T4→T3 conversion problem is the original bottleneck that Wilson's Protocol addresses - impaired DIO1/DIO2 activity means that T4 (levothyroxine) cannot be efficiently converted to active T3, leaving research subjects functionally T3-deficient. The T3→T2 conversion problem is the downstream continuation of the same dysfunction - even when T3 has been restored (either endogenously or via supplementation), the conversion of T3 to 3,5-T2 by the same deiodinase family may still be impaired. The first problem produces T3 deficiency; the second produces T2 deficiency despite T3 adequacy. Both problems share the same root causes (selenium deficiency, inflammation, DIO imbalance) acting on the same enzyme family at successive steps in the conversion cascade.

What deiodinase makes T2 from T3?

The best-characterized enzymatic route from T3 to diiodothyronine products is through DIO1 (type 1 deiodinase), which removes the 3'-iodine from T3 to produce 3,3'-T2. DIO1 is expressed primarily in liver, kidney, and thyroid tissue and is responsible for a large proportion of peripheral T3 catabolism. The production of the metabolically active isomer 3,5-T2 uses overlapping deiodinase machinery - the same enzyme family - though the precise in-vivo enzymatic route for 3,5-T2 synthesis is less completely characterized in the literature than the DIO1→3,3'-T2 pathway. Both conversion products are reduced when DIO1 activity is impaired.

Does selenium deficiency affect T2 production?

Yes - through the same mechanism it affects T3 production. DIO1 is a selenoprotein; its catalytic activity depends on selenocysteine at the active site, which requires adequate selenium for synthesis. When selenium is deficient, DIO1 activity falls, reducing both the T4→T3 conversion and the T3-to-downstream-products conversion. Selenium deficiency is therefore a single-point failure that impairs multiple steps in the thyroid hormone metabolism cascade simultaneously. Researchers investigating the T3→T2 plateau pattern often evaluate selenium status as an early step - restoration of adequate selenium may partially restore conversion capacity before T2 supplementation becomes necessary.

Why doesn't the standard Wilson's WT3 protocol include T2?

Wilson's Protocol was developed in the early 1990s, prior to the detailed mechanistic characterization of T2's cytochrome c oxidase binding published in 1994 and the subsequent two decades of T2 research. The protocol was designed to address the T4→T3 conversion problem as it was understood at that time, using sustained-release T3 to bypass the deiodinase bottleneck and clear rT3 dominance. The T3→T2 conversion step and T2's distinct mitochondrial mechanism were not part of the clinical framework when the protocol was formulated. The T3+T2 combination approach represented in the Wilson's T3+T2 Combo is a research-community extension of the original Wilson's framework, incorporating subsequent mechanistic understanding of T2 biology.

Is the T3→T2 plateau the same as reverse T3 dominance?

No - they are distinct mechanisms that can produce overlapping symptoms, which is part of what makes the plateau pattern difficult to characterize without comprehensive lab work. Reverse T3 dominance is defined by elevated rT3 levels and an impaired FT3:rT3 ratio - DIO3 is overactive, diverting T4 into rT3 rather than active T3. The T3→T2 conversion plateau hypothesis applies in cases where rT3 has been normalized and free T3 is adequate, but metabolic markers continue to underperform. The two can co-exist - a research subject may have both elevated rT3 and impaired T3→T2 conversion - but they are separate problems requiring separate solutions. The rT3 problem responds to the WT3 T3-escalation approach; the T3→T2 problem requires adding T2 directly regardless of T3 dose.

What does a T3+T2 protocol look like?

The T3+T2 combination protocol follows the same cyclic titration structure as the standard Wilson's WT3 approach - sustained-release formulation, every-12-hour dosing, titration in 7.5 mcg increments, temperature endpoint at 98.6°F for three consecutive weeks, then taper - with T2 added at a 1:1 ratio to the T3 dose at each titration step. The rationale for the 1:1 ratio is that it provides direct T2 supplementation at a dose proportional to the T3 being supplied, bypassing the conversion step entirely. The sustained-release formulation ensures both hormones release in the same temporal window for coordinated receptor and mitochondrial activation. The full protocol structure, titration ladder, and monitoring framework are detailed in the Wilson's T3+T2 enhanced protocol guide. The reference product is the Wilson's T3+T2 Combo.

How long does it take to see results from adding T2?

The time course for T2 response has two components. The acute mitochondrial effect - elevated cellular respiration via cytochrome c oxidase - is theoretically rapid, measurable within minutes to hours in animal models. Researchers tracking temperature responses in human-protocol contexts generally report noticing thermogenic and energy changes within the first few days of adding T2 to an established T3 protocol. The slower component is the broader metabolic normalization: body composition changes, sustained temperature stabilization, and resolution of the plateau markers that prompted adding T2 in the first place. Researchers tracking this endpoint in the research-community literature typically report 4-8 weeks as the observation window for meaningful change. The two-component response - rapid initial signal, gradual metabolic normalization - is consistent with T2's dual mechanism: immediate cytochrome c oxidase activation on a timescale of days, longer-term metabolic recalibration on a timescale of weeks.

Closing Note

The T3→T2 conversion problem is research-community theory anchored on real mechanism: documented deiodinase selenium dependence, documented inflammatory suppression of the DIO family, documented T2 cytochrome c oxidase binding (Goglia et al. 1994), and documented T3 protocol plateau patterns that the standard rT3 framework does not fully explain. It is not mainstream endocrinology and has not been validated in controlled clinical trials. What it represents is the logical extension of the Wilson's Protocol framework into the downstream conversion step - a hypothesis that the same dysfunction producing the T4→T3 bottleneck continues operating one step further, into the T3→T2 pathway that supplies the mitochondrial hormone.

For researchers working at this frontier, the 3,5-T2 complete guide covers the foundational mechanism in depth - the cytochrome c oxidase pathway, isomer specificity, TSH safety profile, and what distinguishes T2 research from the T3 conversation. The Wilson's T3+T2 Combo is the reference product for researchers investigating the combined protocol directly. For the full catalog of thyroid research compounds, see the catalog page.